Redhill Biopharma Ltd. (RDHL) Given Buy Rating at Roth Capital

Roth Capital reaffirmed their buy rating on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in a report published on Wednesday. They currently have a $27.00 price target on the biotechnology company’s stock.

RDHL has been the topic of a number of other reports. HC Wainwright set a $33.00 price target on Redhill Biopharma and gave the stock a buy rating in a research report on Wednesday, July 26th. Zacks Investment Research cut Redhill Biopharma from a buy rating to a hold rating in a research report on Wednesday, July 5th. UBS AG assumed coverage on Redhill Biopharma in a research report on Wednesday, September 13th. They set a reduce rating on the stock. Finally, FBR & Co reiterated a buy rating on shares of Redhill Biopharma in a research report on Friday, June 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $24.44.

Redhill Biopharma (NASDAQ:RDHL) traded up 2.48% on Wednesday, reaching $9.90. The company’s stock had a trading volume of 134,972 shares. The firm’s 50 day moving average price is $8.91 and its 200-day moving average price is $9.33. The company’s market capitalization is $169.91 million. Redhill Biopharma has a 52 week low of $8.16 and a 52 week high of $14.74.

Redhill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The firm had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.34 million. On average, equities analysts predict that Redhill Biopharma will post ($2.36) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/10/05/redhill-biopharma-ltd-rdhl-given-buy-rating-at-roth-capital.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its position in Redhill Biopharma by 13.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 12,005 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 1,440 shares during the period. Oppenheimer & Co. Inc. increased its position in Redhill Biopharma by 10.8% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock valued at $220,000 after acquiring an additional 2,500 shares during the period. D.A. Davidson & CO. increased its position in Redhill Biopharma by 10.0% in the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after acquiring an additional 4,000 shares during the period. Family Management Corp increased its position in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock valued at $222,000 after acquiring an additional 8,750 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Redhill Biopharma in the 1st quarter valued at approximately $276,000. Hedge funds and other institutional investors own 10.99% of the company’s stock.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply